Synthesis, Characterization, and Antidiabetic Evaluation of Sequence‐Modified Liraglutide Analogs in a Drosophila melanogaster Model
Biopolymers · 2026-07 · 117 (4)
DOI: 10.1002/bip.70113 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biopolymers, online erschienen am 02.07.2026. Verfasst von Tamira Ravi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Biophysical and Protein Chemistry Lab., Department of Chemistry, National Institute of Technology, Rourkela, India. Hauptthemen laut MEDLINE: Liraglutide, Drosophila melanogaster, Hypoglycemic Agents, Diabetes Mellitus, Experimental. Die Arbeit nennt 73 Literaturangaben. Gefördert von: DST-INSPIRE, DAAD Material Research Program, ANRF-PAIR Program.
Abstract (Originalsprache)
Liraglutide, a glucagon‐like peptide‐1 receptor agonist, is widely used as a therapeutic macromolecule for the treatment of type 2 diabetes; however, its large‐scale production is limited by high manufacturing costs and the frequent occurrence of closely related deletion impurities during synthesis. In the present study, we describe a novel, impurity‐controlled, and industrially feasible synthetic strategy for liraglutide and its sequence‐modified analogs. This method utilizes solution‐phase incorporation of Pal‐γ‐Glu‐OtBu in combination with a preassembled Boc‐His (Boc)‐Ala‐Glu (OtBu)‐OH tripeptide fragment, effectively minimizing the formation of des‐His, des‐Ala, and des‐Glu impurities. The optimized protocol enabled the production of liraglutide and its analogs with consistent isolated yields and high chromatographic purity (> 95% by RP‐HPLC), suitable for subsequent biological evaluation. The antidiabetic potential of liraglutide and three sequence‐modified analogs, Lira (Trp‐O 25 ), Lira (desGly 31 ), and Lira (Glu 17 ), was evaluated using a Drosophila melanogaster model of high‐sucrose diet induced diabetes. Among these, Lira (Glu 17 ) exhibited the most pronounced metabolic improvements, significantly reducing free glucose ( p < 0.001), trehalose ( p < 0.001), and triglyceride levels ( p < 0.001) when compared to diabetic controls. Furthermore, this analog effectively decreased lipid accumulation and reactive oxygen species in larval gut tissues and enhanced locomotor performance in both larva and adult flies. While Lira (Trp‐O 25 ) also demonstrated beneficial effects, Lira (desGly 31 ) showed comparatively limited efficacy. Collectively, this study presents a cost‐effective and impurity‐controlled synthetic platform for liraglutide production and identifies Lira (Glu 17 ) as a promising analog with enhanced antidiabetic activity, offering valuable insights for peptide manufacturing and GLP‐1‐based therapeutic development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biophysical and Protein Chemistry Lab., Department of Chemistry, National Institute of Technology, Rourkela, India.
- Research & Development Department, UNDBIO Co. Ltd, Suwon, South Korea.
- Neuro-Developmental Biology Lab., Department of Life Science, National Institute of Technology, Rourkela, India.
- Centre for Nanomaterials, National Institute of Technology, Rourkela, India.
ORCID-Profile: Monalisa Mishra, Harekrushna Sahoo
Förderung
- DST-INSPIRE
- DAAD Material Research Program
- ANRF-PAIR Program
- NIT Rourkela
- National Institute of Technology Rourkela
Zitieren
APA
Ravi, T., Dash, K., Barman, D. K., Kwon, H., Mishra, M., & Sahoo, H. (2026). Synthesis, Characterization, and Antidiabetic Evaluation of Sequence‐Modified Liraglutide Analogs in a Drosophila melanogaster Model. Biopolymers, 117(4). https://doi.org/10.1002/bip.70113
Vancouver
Ravi T, Dash K, Barman DK, Kwon H, Mishra M, Sahoo H. Synthesis, Characterization, and Antidiabetic Evaluation of Sequence‐Modified Liraglutide Analogs in a Drosophila melanogaster Model. Biopolymers. 2026;117(4). doi:10.1002/bip.70113
BibTeX
@article{Ravi2026,
author = {Ravi, Tamira and Dash, Kalpanarani and Barman, Deep Kumar and Kwon, Hyukjin and Mishra, Monalisa and Sahoo, Harekrushna},
title = {Synthesis, Characterization, and Antidiabetic Evaluation of Sequence‐Modified Liraglutide Analogs in a Drosophila melanogaster Model},
journal = {Biopolymers},
year = {2026},
volume = {117},
number = {4},
doi = {10.1002/bip.70113}
}
EUVIMED